Back to top
more

Argenx (ARGX)

(Delayed Data from NSDQ)

$673.15 USD

673.15
410,783

-1.75 (-0.26%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $672.71 -0.44 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

HSIC Gears Up for Q4 Earnings: Here's What You Need to Know

by Zacks Equity Research

Henry Schein is expected to report impressive sales in both its businesses in the fourth quarter of 2024, along with a positive pace of recovery from the cyber incident.

Zacks Equity Research

BioMarin to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

When BMRN reports fourth-quarter earnings, investors will likely focus on the sales performance of its dwarfism drug Voxzogo.

Zacks Equity Research

Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review

by Zacks Equity Research

The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.

Zacks Equity Research

CRL Gears Up for Q4 Earnings: Here's What You Need to Know

by Zacks Equity Research

Growth across the Manufacturing and RMS segments is likely to have contributed to Charles River's fourth-quarter revenues.

Zacks Equity Research

STE Gears Up for Q3 Earnings: Here's What You Need to Know

by Zacks Equity Research

STERIS' third-quarter fiscal 2025 results are likely to reflect the positives of normalizing the Healthcare backlog and increasing bioprocessing demand.

Zacks Equity Research

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how argenex SE (ARGX) and Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) have performed compared to their sector so far this year.

Zacks Equity Research

ALGN Gears Up for Q4 Earnings: What Lies Ahead for the Stock?

by Zacks Equity Research

Align Technology's fourth-quarter results are likely to reflect the strength in its Systems & Services business.

Zacks Equity Research

IDXX Gears Up for Q4 Earnings: What to Expect From the Stock?

by Zacks Equity Research

IDEXX Laboratories' fourth-quarter 2024 performance is expected to have benefited from a strong execution against strategic priorities.

Zacks Equity Research

Robust Analytical Instruments Segment Likely to Aid TMO's Q4 Earnings

by Zacks Equity Research

Strength in Analytical Instruments and Specialty Diagnostics segments is likely to have driven Thermo Fisher's fourth-quarter 2024 performance.

Zacks Equity Research

Best Momentum Stocks to Buy for January 20th

by Zacks Equity Research

ARGX, ALLT and NGD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 20, 2025.

Zacks Equity Research

New Strong Buy Stocks for January 20th

by Zacks Equity Research

TV, ALLT, CMTG, PLBC and ARGX have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2025.

Zacks Equity Research

Earnings Estimates Rising for Argenx (ARGX): Will It Gain?

by Zacks Equity Research

Argenx (ARGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Are Medical Stocks Lagging Argenx (ARGX) This Year?

by Zacks Equity Research

Here is how argenex SE (ARGX) and Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) have performed compared to their sector so far this year.

Zacks Equity Research

FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab

by Zacks Equity Research

JNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.

Zacks Equity Research

Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Alnylam Pharmaceuticals (ALNY) and argenex SE (ARGX) have performed compared to their sector so far this year.

Zacks Equity Research

Is Butterfly Network (BFLY) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Butterfly Network, Inc. (BFLY) and argenex SE (ARGX) have performed compared to their sector so far this year.

Zacks Equity Research

Why Argenx (ARGX) Might be Well Poised for a Surge

by Zacks Equity Research

Argenx (ARGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how argenex SE (ARGX) and Novartis (NVS) have performed compared to their sector so far this year.

Zacks Equity Research

Zacks.com featured highlights include Argenx SE Alphatec and Olin

by Zacks Equity Research

Argenx SE Alphatec and Olin have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

3 Best Earnings Acceleration Stocks to Buy in a Strong Q4

by Tirthankar Chakraborty

With the advent of a strong fourth quarter, it's prudent to invest in stocks exhibiting solid earnings acceleration such as Argenx, Alphatec Holdings and Olin Corporation.

Zacks Equity Research

Are Medical Stocks Lagging Argenx (ARGX) This Year?

by Zacks Equity Research

Here is how argenex SE (ARGX) and Entera Bio Ltd. (ENTX) have performed compared to their sector so far this year.

Zacks Equity Research

AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why

by Zacks Equity Research

Though Amgen reported encouraging results on two immunology drugs, Wall Street expresses skepticism as the data fell short when compared to existing treatments.

Zacks Equity Research

Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Entera Bio Ltd. (ENTX) and argenex SE (ARGX) have performed compared to their sector so far this year.

Zacks Equity Research

Argenx (ARGX) Moves 4.0% Higher: Will This Strength Last?

by Zacks Equity Research

Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab

by Zacks Equity Research

The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.